Skip to main content

Table 3 Distribution of 38-gene HGF signature expression within non-basal-like tumors (N = 1338), Carolina Breast Cancer Study, 1993–2013

From: Hepatocyte growth factor pathway expression in breast cancer by race and subtype

 

Non-basal-like HGF-negative, N (%)

Non-basal-like HGF-positive, N (%)

Non-basal-like multivariable RFD (95% CI)

Total

1230

108

1338

Agea

   

 < 40 years old

141 (88%)

20 (13%)

5.40% (0.12, 10.67)

 40–49 years old

458 (91%)

43 (9%)

2.06% (− 0.86, 4.98)

 ≥ 50 years old

631 (93%)

45 (7%)

Referent

Raceb

   

 Black

561 (89%)

69 (11%)

5.35% (2.45, 8.26)

 Non-black

669 (94%)

39 (6%)

Referent

Gradec

   

 III

296 (85%)

53 (15%)

10.37% (6.31, 14.42)

 I/II

655 (96%)

25 (4%)

Referent

Stagec

   

 Stage III/IV

193 (86%)

31 (14%)

7.12% (2.25, 1.00)

 Stage II

562 (92%)

52 (8%)

2.24% (− 0.60, 5.10)

 Stage I

458 (95%)

24 (5%)

Referent

Reproductive historyc

   

 Nulliparous

198 (93%)

14 (7%)

− 2.45% (− 6.32, 1.42)

 Parous, breastfed

515 (90%)

39 (7%)

− 1.64% (− 4.7, 1.42)

 Parous, never breastfed

517 (90%)

55 (10%)

Referent

Risk of recurrence scorec

   

 High ROR-PT

128 (79%)

34 (21%)

13.56% (7.09, 20.02)

 Low/medium ROR-PT

1063 (94%)

70 (6%)

Referent

  1. aRelative frequency differences (RFDs) adjusted for race
  2. bAdjusted for age
  3. cAdjusted for race and age
  4. ROR-PT, risk of recurrence score incorporating subtype, proliferation, and tumor size